Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $217.50 short call and a strike $222.50 long call offers a potential 44.93% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $217.50 by expiration. The full premium credit of $1.55 would be kept by the premium seller. The risk of $3.45 would be incurred if the stock rose above the $222.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 45.54 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Growing insurance consortium eyes industry-wide blockchain
Wed, 25 Jan 2017 16:24:09 GMT
Reuters – UK Focus – A consortium set up to explore the use of blockchain technology in the insurance industry plans to announce several new members in the coming weeks, and by 2018 could create an organisation to manage contracts and claims, an executive involved told Reuters. Proponents of blockchain – the database technology that underpins bitcoin – believe it could transform the insurance industry through a shared, transparent record of information, allowing for data transfers in seconds and streamlining communications and transactions. The Blockchain Insurance Initiative (B3i) was created by the world's two largest reinsurers, Munich Re and Swiss Re along with insurers Aegon, Allianz and Zurich.
After hours buzz: CREE, STX, AGN & more
Tue, 24 Jan 2017 22:44:08 GMT
CNBC – Check out Tuesday's after hours buzz: CREE, STX, CXO & more
Drugmakers Plan Huge Deals in 2017 — and Banks Will Collect Big Fees
Tue, 24 Jan 2017 22:32:00 GMT
Endo Resolves FTC Antitrust Suit, But Allergan Hanging; Stocks Mixed
Mon, 23 Jan 2017 21:27:03 GMT
Allergan Stock is Still Struggling Amid FTC Ruling
Mon, 23 Jan 2017 19:49:00 GMT
Also on Market Tamer…
Follow Us on Facebook